DRNA - Novo Nordisk Gets A Bargain With Dicerna Acquisition

• Novo Nordisk will acquire Dicerna for $3.3 billion in cash.
• The acquisition makes sense for Novo Nordisk as it eliminates the milestones and royalties it would need to pay Dicerna for partnered candidates.
• The deal also brings Dicerna's wholly-owned hepatic and extrahepatic drug discovery platform and pipeline and potential milestones and royalties from several partners.
• Based on the broad potential of Dicerna's pipeline, I believe Novo Nordisk is getting a bargain.
• A higher bid could emerge but chances are slim and the deal should close soon.

For further details see: